Results 21 to 30 of about 1,669,550 (354)
Type I interferon: potential therapeutic target for psoriasis? [PDF]
PLoS ONE, 2008 BACKGROUND: Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation.
Yihong Yao +10 more
doaj +1 more source
Biomolecules, 2021 There is a great deal of evidence pointing to interferons (IFNs) as being key cytokines in the pathogenesis of different systemic autoimmune diseases, including primary Sjögren’s syndrome (pSS).
Nicoletta Del Papa +8 more
doaj +1 more source
Type-I interferons in atherosclerosis [PDF]
Journal of Experimental Medicine, 2019 The contribution of dyslipidemia and inflammation in atherosclerosis is well established. Along with effective lipid-lowering treatments, the recent success of clinical trials with anti-inflammatory therapies and the accelerated atherosclerosis in many autoimmune diseases suggest that targeting inflammation may open new avenues for the prevention and ...
Hung-Jen Chen +2 more
openaire +2 more sources
Antiproliferative Properties of Type I and Type II Interferon
Pharmaceuticals, 2010 The clinical possibilities of interferon (IFN) became apparent with early studies demonstrating that it was capable of inhibiting tumor cells in culture and in vivo using animal models.
Joseph Bekisz +4 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2021 Background Improvement of radiotherapy efficacy requires better insight in the dynamic responses that occur during irradiation. Here, we aimed to identify the molecular responses that are triggered during clinically applied fractionated irradiation ...
Ruben S. A. Goedegebuure +15 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background We previously demonstrated that ischemically injured cardiomyocytes release cell‐free DNA and HMGB1 (high mobility group box 1 protein) into circulation during reperfusion, activating proinflammatory responses and ultimately exacerbating ...
Lina Lai +5 more
doaj +1 more source
Loss of Ifnar1 in Pancreatic Acinar Cells Ameliorates the Disease Course of Acute Pancreatitis. [PDF]
PLoS ONE, 2015 Type I interferon constitutes an essential component of the combinational therapy against viral disease. Acute pancreatitis is one side effect of type I interferon-based therapy, implying that activation of type I interferon signaling affects the ...
Katharina J Miller +7 more
doaj +1 more source
Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
Frontiers in Immunology, 2021 Type I interferons (IFN-I) were first discovered as an antiviral factor by Isaacs and Lindenmann in 1957, but they are now known to also modulate innate and adaptive immunity and suppress proliferation of cancer cells.
Megen C. Wittling +3 more
doaj +1 more source
Type I interferon induces cancer stem cells-mediated chemotherapy resistance
OncoImmunology, 2022 In a recent study in Nature Immunology, Musella et al. demonstrate that suboptimal type I interferon (IFN-I) signaling in tumors undergoing immunogenic cell death (ICD) facilitates the accumulation of cancer stem cells (CSCs) by triggering the epigenetic
Mara De Martino, Claire Vanpouille-Box
doaj +1 more source
Frontiers in Immunology, 2021 The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative pathogen of current COVID-19 pandemic, and insufficient production of type I interferon (IFN-I) is associated with the severe forms of the disease.
Liyan Sui +8 more
semanticscholar +1 more source